Dear Colleagues:

I am writing to thank you all for a wonderful year as President. Working together we have accomplished a great deal and we even had fun doing it! The 2008 spring meeting was a great success with wonderful presentation at both the SBUR/SUO morning session and the afternoon sessions which were chaired beautifully by Dr. Rosalyn Adam and Dr. Marianne Sadar. Thanks to the enormous effort of Dr. Shuk Mei Ho, Dr. Vinata Lokeshwar and the organizing committee the fall meeting was scientifically robust, exciting and fun! We heard talks and view posters from extraordinary young scientists and as a bonus we even found out that sombreros make beautiful accessories!

Perhaps the most exciting achievement for me has been the development of dynamic and reciprocal interaction with the new leadership of the AUA Foundation. As members of the SBUR many of you have given generously of your time to the AUA and its research efforts. In October 2008 our good friend Dr. Leo Giambarresi joined the Foundation to be the Director of Research. Through our interactions with Leo, and his extraordinary colleague Mr. Rodney Cotton, we realized that a more structured and regular interaction between the SBUR and AUA Foundation was needed to achieve our mutual goals. In the ensuing months, Leo, Rodney, and I have worked diligently to develop this interaction.

To solidify this relationship, I now have biweekly conference calls with Leo and Rodney and they participate in the monthly conference calls of the SBUR Executive Committee. Our incoming President Dr. Simon Hayward will continue this practice. Since there is no substitute for face-to-face interactions, I recently traveled to Baltimore and met with the Foundation Director, Dr. Sandra Vassos, and met many of the people who work at the Foundation. I order to capitalize on the momentum of the past few months we are going to test the utility of the Past President serving as the SBUR liaison to the AUA Foundation. In this capacity I expect to return at least twice yearly for similar visits and possibly to serve on committees or groups as requested by the AUA Foundation leadership and/or our new President, Dr. Simon Hayward. I will serve in the liaison position during this “test year” and will report back to the SBUR Executive Committee on the specific commitments of this post. It is my hope that my legacy as President will include the forging of a productive and lively interaction with the Foundation.

It has been an honor to serve as President of his organization and it continues to be a sheer delight to be a part of the SBUR family.

Gail Prins, Ph.D.: Dr. Prins has been selected to receive the 2009 Joint SWIU/Society for Basic Urologic Research (SBUR) Award for Excellence in Urological Research. She will receive this award at the Society of Women In Urology meeting which will take place in Chicago during the AUA-2009 Meeting.
Phoenix - Fall 2008 Meeting Report

The 18th Fall SBUR Meeting in Phoenix, Arizona was a grand success. The meeting’s theme was *Epigenetics and Genitourinary Disorders*. Under the leadership of **Dr. Shuk-mei Ho**, the Program Committee put together a strong scientific program where the attendees learned about the latest advancements in the field of epigenetics (e.g. micro-RNA, DNA methylation, histone modification) and their applications to investigative research in GU diseases. The trainees had ample opportunities to network with peers and senior members of the Society during poster sessions. In all twenty-four travel awards were given to student, fellows and residents. The awardees were selected from a pool of eighty-three submitted abstracts. In addition, the Prostate Cancer Action Foundation generously provided travel support for two junior investigators. The gala dinner was a fun filled activity for all attendees, some of whom danced to the Latin tunes. With the success of the meeting in Phoenix, Arizona stay tune for the Fall 2009 Meeting in New Orleans Louisiana, which is the 8th World Basic Urological Research Congress.
Come & Experience 
Southern Hospitality:  
The 8th World Basic Urological Research Congress 
Venue: Sheraton New Orleans 
Dates: November 5th – 8th, 2009 

The objective of this 8th World Urological Research Congress is to strengthen the ongoing dialogue between basic and clinical scientists in our study of urologic disease and genitourinary tract health. Our goals are to accelerate the translation of new diagnostic and prognostic markers and treatments to the patient bedside, identify and exploit novel molecular and cellular targets, and learn about new experimental strategies, concepts and cutting-edge technologies. The meeting should provide a unique opportunity to forge new cross-disciplinary collaborations in urology research in an intimate setting.

An exciting feature of this World Congress is the first ever “Grants How-To” workshop. The format of this session is still in the developmental stages but we intend to invite Program Directors and officers from the Center for Scientific Review at the National Institutes of Health, Program Directors from the Department of Defense, American Urological Association Foundation and Veterans Administration. This will be an interactive forum with heavy emphasis on Q&A from the meeting participants and one-on-one interactions between meeting attendees and grant officials. To enhance the interaction between young and established investigators, for the first time, we have planned a job fair where students, residents and fellows will have a chance to seek job opportunities in urological research. An exciting Product Show is also planned.

Another first in this World Congress is the “First Leland Chung Lecture”. Students, fellows, colleagues, well wishers and friends of Dr. Leland Chung, Emory University, Atlanta, GA, have established the Leland Chung Lectureship at the SBUR. The first Leland Chung lecture will be delivered by Dr. Donald Coffey.

Take a look at the Preliminary Program and you know why it is a must to attend this meeting, not to mention all the fun that you will have walking the French Quarter on cool Autumn nights under the starry skies!

The Preliminary Program is printed at the end of this newsletter.

Also printed at the end is the SBUR-SUO Spring 2009 Joint Meeting Program (AUA, Chicago, May, 2009).
It is that time of the year again. It is time to exercise your fundamental right to vote and elect a new Vice President, Treasurer, and Member-at-large. The nominating committee has suggested the names of phenomenal candidates. The Spring Newsletter is proud to introduce these candidates to our SBUR members. Each candidate has given their time to put together a synopsis of who they are and what is their vision for the SBUR. Please take a moment to read these synopses and exercise your right to VOTE! Elected Executive Committee members will be announced at the Spring SBUR Meeting member’s Luncheon, which will be held on Saturday April 25, 2009.

Position: Vice President

David Frazier Jarrard, M.D.: Dr. Jarrard obtained a BS in Art History/Chemistry and subsequently an MD from the University of Virginia. He was a resident in Urology at the University of Chicago. He subsequently was a American Foundation for Urologic Disease scholar at the Brady Urologic Institute of the Johns Hopkins Hospital. Dr. Jarrard is currently a Professor of Urology and Molecular and Environmental Toxicology at the University of Wisconsin. He holds the John Livesey Chair in Urologic Oncology and is Vice Chair of the Department. He is a member of the University of Wisconsin Institute on Aging, the American Association of Cancer Research, the American Urological Association, the Eastern Cooperative Oncology Group, the Society for Urologic Oncology, and the Society for Basic Urologic Research (since 1994). He has active basic science and translational research interests supported through the National Institutes of Health (R01, P01), the Prostate Cancer Foundation, and the Department of Defense Prostate Cancer Research Program. He has served as a reviewer for the NIH, and chaired research panels for the DOD PCRP. He was a recipient of a SBUR Young investigator Award in 2001. He has previously served as the elected member-at-large for the SBUR (2007-2009) and is on the organizing committee for the fall meeting in New Orleans.

Research interests: The Jarrard lab is currently focused on two understudied aspects of prostate tumor biology. One question addresses the role of epigenetics and prostate cancer susceptibility with aging. We have found that the peripheral zone of the prostate from men with prostate cancer commonly contains a loss of the normal genomic imprint for Igf2 (Clin Can Res 1996), and that this occurs through an age-related degradation of imprinting (Can Res, 2008). A loss of CTCF binding during aging underlies the relaxation in Igf2 imprinting seen during aging in the mouse and in human prostate cell senescence (JBC, 2005). These findings are the first to indicate that epigenetic changes may play a major role in the age-related susceptibility of men developing prostate cancer, and future efforts are focused on reversing this process and its role as a marker. A second area of research addresses the question of whether cellular senescence can be reinvoked in cancer cells as therapy. We have examined a number of molecular pathways involved in senescence induction in prostate epithelial cells (Can Res, 1999, Oncogene 2002, JBC 2002) and have found that chemotherapy active in prostate cancer may reinvoke this phenotype (Neoplasia 2005). The senescent phenotype has no detrimental effect on surrounding cancer cells (JBC, 2008). Current efforts are underway identifying novel small molecules that induce senescence and their role in vivo.

Vision statement: From early on in my career, the SBUR provided guidance and support for my endeavors as a physician-scientist, and played an integral role in my research success. I look forward to our biannual meetings for both the exciting science, but also the wonderful fellowship. I am committed to promoting the SBUR as a scientific training environment to foster the career development of PhD and MD urologic researchers. From my position on the executive board and over the last 15 years, I have come to realize what an important moment this is for the society. Important initiatives include working closely with the AUA Foundation and the rest of the AUA in developing and implementing new and existing programs that will advance urologic research. This will solidify the society’s leadership role and continue to foster a healthy and mutually beneficial relationship with the AUA. Largely because of the SBUR, there is visibility for Urology research at the national level. This is increasingly important given the ongoing fight for limited research resources. I will seek to influence major funding agencies by enhancing the society’s participation in funding and policy-making processes. In addition, it will be important to expand our own fundraising activities through our website and other industry sources. Finally, the membership welcomes research from all venues, and this diversity is something I look forward to advancing. I would encourage the expansion of our society by new initiatives to involve both MD and PhD trainees and junior faculty. This will generate a foundation for future growth and solvency. In addition, promoting the involvement of other urologic research groups in our meetings, including epidemiology/public health, would enrich and grow the society. It would be an honor to continue to serve the society in this capacity as Vice President.
**Alice C. Levine, M.D.:** Dr. Levine obtained her medical degree from Columbia University College of Physicians and Surgeons followed by a residency in internal medicine at the New York University Medical Center. She completed her Fellowship in Endocrinology and Metabolism at Mount Sinai Medical Center in New York City. During her Fellowship she studied the effects of medical castration on prostate size and symptoms in men with benign prostatic hyperplasia and was the first to publish on the successful medical management of this disorder. Dr. Levine is a longstanding Faculty Member of the Mount Sinai School of Medicine and has served as the Director of the Medical Student Course in Endocrine Diseases since 1995. She is also the Director of Research Training for the Division of Endocrinology and has served as mentor for undergraduate, graduate, and medical students. She is a sought-after teacher and mentor for post-doctoral fellows and Junior Faculty members. She gives a course to trainees on how to present clinical and scientific data. Dr. Levine and her longstanding collaborators (Xin-Hua Liu, Ph.D. and Alexander Kirshenbaum, M.D., Associate Professor of Urology) have published over 40 articles in peer-reviewed journals in the field of prostate research. Dr. Levine’s laboratory has been continuously funded for more than twenty years, receiving grants from the National Institutes of Health, Department of Defense, Martell Foundation for Leukemia, Aids and Cancer Research, American Federation of Aging Research, New York Academy of Sciences, Hans Schapira MD Urologic Research Fund, Prostate Action, Inc., CaP Cure, and American Federation of Aging Research. She has been a member of the DOD Study Section since the inception of the Prostate Cancer IMPACT program and has also served on several NIH and VA Study Section Special Emphasis Panels.

**Research Interests:** Her laboratory focuses on the interactive effects of sex steroids, growth factors and cytokines in stromal-epithelial interactions in prostate development and diseases. Research highlights include their demonstration that in vivo treatment of prostate cancer tumor-bearing mice with cyclooxygenase-2 (COX-2) inhibitors dramatically shrinks tumor size and decreases tumor angiogenesis. Her group also reported on the role of COX-2 in prostate cancer cell under conditions of hypoxia. They recently reported that androgens fertilize the bone stromal microenvironment and promote the growth of prostate cancer cells in bone. Dr Liu, Senior Scientist in the Levine Laboratory, recently isolated a protein from dietary bitter melon seeds that induces apoptosis selectively in malignant prostate cells. In collaboration with Drs. Shuk-Mei Ho, Yong Yuan and Ying Wai Lam from the University of Cincinnati School of Medicine, we analyzed the protein with Mass Spectrometry and found that it consists solely of two highly-related ribosomal inactivating proteins (RIPs). Our upcoming publication in the International Journal of Cancer is the first to report that plant-derived RIPs can epigenetically modulate prostate cancer cells and function as histone deacetylase (HDAC) inhibitors.

**Vision Statement:** Many of the most rewarding research projects in my laboratory have been a result of collaborations that were forged as a member of the Society for Basic Urologic Research. This organization is perfectly poised to foster collaborative efforts between Junior and Senior Investigators, Clinicians and Basic Scientists. The relatively relaxed and intimate setting of the semi-annual meetings of the Society not only helps to foster collaborations but also serves as an excellent forum for young investigators and trainees to present their work. If elected, I would continue to include outside speakers at these meetings to speak on a variety of cutting-edge topics. I would also be active in obtaining more travel awards and training grants, from the public and private sectors. First and foremost, the SBUR needs to continue to be a place where trainees and junior investigators are encouraged and mentored so that they can have successful careers in urologic research.

**Denise O’Keefe, Ph.D.:** Dr. O’Keefe received her Ph.D. in Medicine at the University of Adelaide, Australia in 1996. She then studied genomic imprinting in the laboratory of Dr. Ben Tycko at Columbia University, followed by a postdoctoral fellowship studying Prostate Specific Membrane Antigen in the laboratory of Dr. Skip Heston at Memorial-Sloan Kettering Cancer Center, and then the Cleveland Clinic. Dr. O’Keefe is currently an Assistant Professor of Urology at the University of Pittsburgh and has been a member of SBUR since 2007, when she received the SBUR Young Investigator award.

**Research Interests:** Dr. O’Keefe’s main research interest is in studying the epige-
urologic researchers, the SBUR will continue to be dynamic and maintain and strengthen its predominant stature worldwide in urological research.

Allen Gao, M.D., Ph.D.: Dr. Gao is currently the Ralph deVere White Professor, Director of Urologic Research, and Co-Leader of Prostate Cancer Program, Department of Urology and UC Davis Cancer Center, University of California at Davis. He received his Ph.D (1995) in Molecular Biology at The University of Texas MD Anderson Cancer Center, Houston, TX and his MD (1985) at Sichuan University West China Medical Center, China. He completed a postdoctoral fellowship (1995-1998) in the Department of Urology and Oncology at Johns Hopkins University School of Medicine, Baltimore, MD. Dr. Gao served as an Assistant Professor of Urology (1998-2002) at University of Pittsburgh, Associate Professor (2002-2006) and Professor (2006-2007) of Medicine and Pharmacology at Roswell Park Cancer Institute and SUNY at Buffalo prior to relocating to the University of California at Davis.

Marianne Sadar, Ph.D.: Dr Sadar received her B.Sc. degree in Biochemistry from Simon Fraser University in Burnaby BC, Canada and her Ph.D. in Molecular Biology from the University of Bradford, in the United Kingdom in 1995. Postdoctoral fellowships were done at Astrazeneca in Sweden followed by the BC Cancer Agency in Vancouver, Canada. Dr. Sadar is currently an Associate Professor of Surgery, Program Leader for Prostate Cancer Research and Senior Scientist in the Genome Sciences Centre at the BC Cancer Agency. She has served on more than 30 grant review panels and is a full member of the NIH Drug Discovery & Molecular Pharmacology Study Section. Dr. Sadar is an active member and participant of the SBUR and its functions.

Research Interests: Dr. Sadar’s research interests include the molecular mechanisms of hormonal progression of prostate cancer and development of therapeutic strategies for improved clinical management of advanced disease.

Vision Statement: The SBUR plays a leadership role for Basic Urologic Research in North America. In this role, the SBUR is important for the exchange of research, networking, career development and training, and provides a venue for recruitment of young scientists and postdoctoral fellows. Efforts to expand the SBUR’s affiliations with other urological associations around the world will continue to strengthen and fulfill its mandate. It is important to continue to enhance the SBUR’s role in bringing together clinicians and basic scientists to facilitate collaborations in expediting translational research and realizing novel approaches for clinical trials. Thus relationships between the SBUR and the American Urological Association and other Urological Associations around the world should be a priority as well as targeting membership to residents, young investigators and junior faculty members. By increasing membership of the next generation of urologic researchers, the SBUR will continue to be dynamic and maintain and strengthen its predominant stature worldwide in urological research.
**Research interests:** Dr. Gao’s research interests focuses on understanding molecular mechanisms associated with progression of castration-resistant prostate cancer and metastasis to bone with the goal of identification of potential therapeutic targets for prostate cancer. Particular emphasis includes aberrant androgen receptor activation by cytokines, selenium chemoprevention and therapy, and targeting cell signaling pathways in prostate cancer. Dr. Gao’s research is actively funded by grants from the NIH and DOD, as well as through foundation grants. He has published over 30 articles on the area of urological cancers. Dr. Gao currently serves on the Editorial Board of The Prostate.

**Vision Statement:** I joined the SBUR in 1998 and became a lifetime member in 2004. I have obtained extensive research experience and broad background in urological diseases during my 20 years training and research career, providing me with a unique perspective that may be beneficial to the members of the SBUR. Based on my own experience, my vision for the SBUR is to encourage a multidisciplinary translational research, to attract young scientists and physician-scientists to the field of urological research, and to continue to lobby for funding to support urological research. As a Member-at-Large, I will strive to promote the best interests of the SBUR and its members by increasing membership in the SBUR not only in US, but worldwide to include more young basic scientists and physician-scientists, and those who are in training; by working with patients advocacy to increase voice for supporting urological research and to further strengthen the SBUR financial health; by promoting the SBUR meetings as the educational and training opportunities for young investigators to advance their urological research career. I believe that, with dedicated members who can provide substantial infrastructure, the SBUR will continue to succeed and I look forward to the opportunity to serve the SBUR.

Beatrice Knudsen, M.D.: Dr. Knudsen is a molecular pathologist at the Fred Hutchinson Cancer Research Center. Dr. Knudsen’s medical training began with an internship in internal medicine at the New York Hospital Cornell Medical College and continued after a post-doctoral training at the Rockefeller University in the laboratory of molecular oncology and signal transduction with a pathology residency and board certification at the New York Hospital. Dr. Knudsen has since conducted independent research in prostate cancer with support from the NIH, DOD and Prostate Cancer Foundation. She has also worked with industrial partners to develop tools for tissue-based analysis. In the laboratory, Dr. Knudsen has enjoyed the company of students, post-doctoral fellows, residents and clinical fellows with whom she published > 50 papers.

**Research interests:** The laboratory’s translational research program is in the area of molecular pathology and prostate cancer. We develop and test prognostic and treatment associated biomarkers, with the goal of improving the life expectancy and quality of patients with metastatic prostate cancer. Our scientific interest focuses on epithelial to mesenchymal transition (EMT), which comprises a cellular program that facilitates tumor metastasis. A hallmark of EMT is the loss of E-cadherin expression. Based on our observation 10 years ago that prostate cancer cells transition between E-cadherin positive and negative phenotypes, we are interested to understand how the E-cadherin status affects the interactions of cancer cells with the microenvironment in the bone marrow. The EMT-associated pathways that we study include those regulated by the c-MET cell surface receptor tyrosine kinase, cell-cell adhesion proteins (i.e. E-cadherin), and the CUB domain cell surface protein, Gp140/CDCP1. Further, we translate and confirm the data obtained in our twodimensional cultures in patient tissues, three-dimensional cell culture systems and primary cell cultures. In addition to research in prostate cancer metastasis, we recently expanded the molecular pathology program to participate in a nutritional intervention trial. Men are stratified before radical prostatectomy to ingest a broccoli sprout extract that contains high levels of sulforaphane (SFN). We discovered a novel activity of SFN that potentially regulates the amount of androgen in the prostate and are studying this and other SFN related pathways and biomarkers in tissue and blood samples from the nutritional intervention trial.

**Vision statement:** Over several years, I enjoyed participating in the community of the SBUR. The SBUR has provided a fantastic forum for scientific exchange of ideas for me and members of my research group. We enjoy the yearly SBUR scientific meetings and each year we broaden our scientific and technical knowledge and make new friends. This is due to the collegial atmosphere and the high level of scientific presentations at the SBUR meetings. As a pathologist, I would like to help SBUR investigators with translating molecular concepts from the laboratory to patient cancers and provide assistance with requesting tissues from repositories and with tissue imaging. I am interested in participating in the educational and the New Investigator programs to recruit molecularly trained young scientists to the field of urological diseases. I would also like to establish a searchable SBUR website, listing resources and technologies that can be shared amongst SBUR members through collaborations. In summery, I will do my best to strengthen the SBUR community by facilitating communication, event planning, mentoring and celebrating.
The SBUR Newsletter
March 2009

Editor:
Vinata Lokeshwar
SBUR Secretary (2008 – 2010)
Department of Urology (M-800)
University of Miami, Miller School of Medicine
P.O. Box 016960, Miami, FL 33101
e-mail: vlokeshw@med.miami.edu

Editorial Assistance:
Ms. Sue O'Sullivan
WJ Weiser & Associates, Inc.
Two Woodfield Lake
1100 East Woodfield Road, Suite 520
Schaumburg, IL 60173
Phone: 847-517-7225
Fax: 847-517-7229
Website: www.sbur.org

Graphics & Design:
Karl X. Chai
Past SBUR Secretary (2006 – 2008)
University of Central Florida
4000 Central Florida Boulevard
Orlando, FL 32816-2364

e-mail: info@sbur.org

Two Woodfield Lake
1100 East Woodfield Road, Suite 520
Schaumburg, IL 60173
Phone: 847-517-7225
Fax: 847-517-7229
Website: www.sbur.org
The 8th World Basic Urological Research Congress

Preliminary Program

Organizing committee
Chair: Vinata B. Lokeshwar, Ph. D., University of Miami, Florida

Members:
David Jarrard, M.D., University of Wisconsin, Wisconsin, USA
Shuk-mei Ho, Ph.D., University of Cincinnati, Ohio, USA
Chris Winters, M.D. Louisiana State University Health Science Center, Louisiana, USA
Zoran Culig, Ph.D., Innsbruck Medical University, Austria
Anders Bjartell, MD, PhD, Malmö University Hospital, Lund University, Sweden

Thursday November 5, 2009

12:00 p.m. – 9:00 p.m.  Registration

3.00 p.m. – 6.00 p. m.  Grants-How To Workshop

7:20 – 7.30 p.m.  Welcome, introductory remarks
Simon Hayward, Ph.D., Vanderbilt University, Nashville, USA
SBUR President (2009 – 2010)

7.30 – 9.00 p.m.  Plenary Session I: Markers and treatments: laboratory to clinic

7.30 – 7.40 p.m.  Introduction

7.40 – 8.20 p.m.  Kapil Bhalla, M.D. Medical College of Georgia, Augusta, USA
Title: Targeting the nexus of heat shock and metabolic stress responses in cancer

8.20 – 9.00 p.m.  Henrik Grönberg, Ph.D. Karolinska Institute, Stockholm University, Stockholm, Sweden
Title: (TBA)
Friday November 6, 2009

7:00 a.m. – 7:00 p.m.  Registration

7:00 a.m. – 7:55 a.m.  Continental Breakfast

8:00 a.m. – 12:25 p.m.  Plenary Session II: Matrix, cytokine and chemokine Targets

8.00 – 8.10 a.m.  Introduction

8.10 – 8.40 a.m.  Allen Gao, M.D., Ph.D. University of California Davis, Davis, USA  
Title: Targeting interleukin-6 signaling for castration-resistant prostate cancer

8.40 – 9.10 a.m.  Jill A. Macoska, Ph.D. University of Michigan, Detroit, USA  
Title: Chemokines As Mediators Of Benign And Malignant Prostatic Disease

9.10 – 9.40 a.m.  Kerstin Junker, M.D., Friedrich-Schiller-University Jena, Germany  
Title: Understanding molecular mechanisms of metastasis in renal cell carcinomas: basis for targeted therapy.

9.40 – 10.10 a.m.  Coffee Break

10.10 – 10.40 a.m.  Michael Henry, Ph.D. University of Iowa, Iowa City, USA  
Title: An emerging role for dystroglycan in prostate cancer

10.40 – 11.10 a.m.  Rajvir Dahiya, Ph.D., University of California San Francisco, San Francisco, USA  
Title: Molecular biomarkers for urological malignancies

11.10 – 11.40 a.m.  Gert Mayer, M.D., Innsbruck Medical University, Innsbruck, Austria  
Title: Tubular atrophy and interstitial fibrosis in chronic kidney disease, new pathways, markers and treatment options

11.40 – 12.10 p.m.  Hing Leung, M.D., Beatson Cancer Institute, Glasgow, UK  
Title: Evaluation of the MEK5/ERK5 signalling pathway as a potential target for therapy in prostate cancer.

12.10 – 12.30 p.m.  Travel Award Winner (TBA)

12:25 p.m. – 1:35 p.m.  Lunch
1:35 p.m. – 5:30 p.m. **Mini Symposium I**: Dialogues in Clinical and Translational Research

1.35 – 1.40 p.m. Introduction

1.40 – 2.10 p.m. Deborah Erickson, M.D., University of Kentucky, Lexington, USA
**Title:** Molecular Targeting for Diagnosis and Treatment of Interstitial Cystitis/Painful Bladder Syndrome

2.10 – 2.40 p.m. Jordan Dimitrakov, M.D., Ph.D. Children’s Hospital/Harvard Med School, Boston, MA
**Title:** Chronic pelvic pain - Mind over Matter?

2.40 – 3.10 p.m. Chris Winters, M.D., Louisiana State University Health Sciences Center, New Orleans, USA
**Title:** Neuromuscular Dysfunction of the Lower Urinary Tract and Pelvic Floor: A Clinician’s Perspective of Research Needs

3.10 p.m. – 3.30 p.m. **Coffee Break**

3.30 – 4.00 p.m. Yanir Lotan, M.D., UT Southwestern Medical Center, Dallas, USA
**Title:** Cost-effectiveness of Urine-based Tumor Markers for Bladder Cancer: Current and Potential Uses

4.00 – 4.30 p.m. James Mohler, M.D., Roswell Park, Buffalo, USA
**Title:** Androgen-Independent Prostate Cancer is not Androgen Independent

4.30 – 5.00 p.m. Henk van der Poel, M.D., Netherlands Cancer Institute, Amsterdam, The Netherlands
**Title:** mTOR/Pim1 signaling in prostate cancer progression

5.00 – 5.30 p.m. Axel Merseburger, M.D. Hannover Medical School, Hannover, Germany
**Title:** Molecular markers as independent predictors of Response to neoadjuvant chemotherapy in muscle-invasive bladder cancer

5:30 p.m. – 7:30 p.m. **Poster Session I with reception**

5.30 p.m. – 7.30 p.m. **Job Fair I (Concurrent with Poster Session)**
Saturday, November 7th  2009

7:00 a.m. – 1:00 p.m.  Registration

7:00 a.m. – 7:45 a.m.  Continental Breakfast

7.50 a.m. – 11:15 p.m.  Plenary Session III: Targeting Cell Signaling

7.50 – 8.00 a.m.  Introductory Remarks

8.00 - 8.30 a.m.  K. C. Balaji, M.D. University of Massachusetts, Worcester, USA
Title: Protein Kinase D1 (PKD1): A Protein of Emerging Translational Interest in Prostate Cancer

8.30 – 9.00 a.m.  Sanjay Gupta, Ph.D. Case Western Reserve University, Cleveland, USA
Title: NFKB: A Molecule of Diagnostic and Therapeutic Value in Prostate Cancer

9.00 – 9.30 a.m.  Karen Knudsen, Ph.D. Thomas Jefferson University, Philadelphia, USA
Title: Cell cycle dysregulation in prostate cancer: impact on AR signaling and therapeutic response

9.30 – 10.00 a.m.  Häkan Axelson, Ph.D. Lund University, University Hospital MAS, Malmö, Sweden
Title: Notch signaling in kidney cancer

10.00 – 10.20 a.m.  Coffee Break

10.20 – 10.50 a.m.  Johannes Vieweg, M.D. University of Florida, Gainesville, USA
Title: Biologic Therapy in Urologic Oncology

10.50 a.m. – 11.15 a.m.  Travel Award Winner (TBA)

11.15 a.m. – 12.15 p.m.  Plenary Session IV: Dr. Leland Chung Lecture

Dr. Donald Coffey, Johns Hopkins University, Baltimore, USA
Title: A view of the past, present and future research in urology, spanning the Leland Chung period, and beyond.

12.20 - 1.35 p.m.  Lunch (on your own)

Afternoon Free
5:00 p.m. - 6:45 p.m.  Poster Session II

5:00 – 6.45 p.m.  Job Fair II (Concurrent with Poster Session II)

7:00p.m. - 10:00p.m.  Banquet & Entertainment - TBA

7:45p.m- 8:15 p.m.  SBUR Meritorious Award – Presentation (TBA)

Sunday, November 8th 2009

7:00 a.m. – 11:00 a.m.  Registration

7:00a.m. - 7:45a.m.  Continental Breakfast

7:45 a.m. - 11:30p.m.  Plenary Session V: Novel approaches for biomarkers and therapy

7.45 – 7.55 a.m.  Introductory Remarks

7.55 – 8.25 a.m.  Dr. Michael Freeman, Children’s Hospital, Harvard University, Boston, USA

Title: Lipid Metabolism and Signal Transduction in Cancer

8.25 – 9.05 a.m.  Leland Chung, Ph.D. Emory University School of Medicine, Atlanta, USA

Title: Biology and Targeting of the Plasticity of Prostate Cancer Cells

9.05 – 9.35 a.m.  Charles Rosser, M.D. Univ. of Florida, Gainesville, USA

Title: Bladder Cancer Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia

9.35 – 10.5 a.m.  Leendert Hj Looijenga, M.D., Erasmus Medical Center-University Medical Center Rotterdam, Rotterdam, The Netherlands

Title: Human germ cell tumors: from biology to clinic.

10.05 – 10.30 a.m.  Travel Award Winner (TBA)

10:30 a.m. – 10:50 a.m.  Coffee Break

10.50 a.m. – 11:40 a.m.  Plenary session VI: AUA Speaker

Dr. Dan Theodorescu University of Virginia, Charlottesville, USA
Title: Targets to therapies: Discovery and Translation in advanced bladder cancer

11.40 – 11.50 a.m.

Farewell
Simon Hayward, Ph.D. Vanderbilt University, Nashville, USA
The Society of Basic Urologic Research & The Society of Urologic Oncology

presents

Translation of Basic Science into Clinical Applications

Welcome

8:00 a.m. – 8:05 a.m. Co-Chairs
Dr. Johannes Vieweg, University of Florida (SUO)
Dr. Simon Hayward, Vanderbilt University Medical Center (SBUR)

Investigation into Tumor Microenvironment

8:05 a.m. – 8:25 a.m. Aging and Senescence in the Prostate Microenvironment: Time Does Not Heal All Wounds...
Peter S. Nelson, MD, Fred Hutchinson Cancer Center

8:25 a.m. – 8:45 a.m. Of Nerves and Prostate Cancer
Gustavo Ayala, MD, Baylor College of Medicine

8:45 a.m. – 9:05 a.m. Pre-clinical and clinical development of vitamin D-mediated strategies to target prostate cancer microvasculature.
Candace Johnson, PhD, Roswell Park Cancer Institute

9:05 a.m. – 9:20 a.m. Podium Discussion

Cancer Immunotherapy

9:25 a.m. – 9:45 a.m. How to Elicit Immune Responses Against Cancer
Suggested Speaker: Eli Gilboa, PhD

9:45 a.m. – 10:05 a.m. Combinatorial Immunotherapy for Prostate Cancer
Suggested Speaker: Charles Drake, MD, PhD

10:05 a.m. – 10:25 a.m. Immune Responses to Human Prostate Cancer – Clinical Experience
Suggested Speaker: Lawrence Fong, MD (UCSF)

10:25 a.m. –10:40 a.m. Podium Discussion

The Coffey Lectureship

10:45 a.m. – 11:45 a.m. Theresa Guise, MD, University of Virginia: Transforming Growth Factor Beta: Cancer, Bone and Beyond

11:45 am - 1:15pm Annual SBUR Members Lunch

1:30 pm – 3:30pm Afternoon Breakout Sessions
AFTERNOON BREAKOUT SESSIONS
Each speaker will present a 20 minute talk followed by 10 minutes for discussion

SESSION A: Bladder diseases and mechanisms of therapy.

Location:

1:30 p.m. – 1:35 p.m. Welcome and Overview
Neil Bhowmick, PhD, Vanderbilt University Medical Center, Chair

1:35 p.m. – 2:05 p.m. Signaling mechanisms potentiated by bladder inflammation
Wade Bushman, MD, PhD, Department of Urology, University of Wisconsin

2:05 p.m. – 2:35 p.m. Immune mechanisms for treating bladder cancer
David McConkey, PhD, M.D. Anderson Cancer Center

2:35 p.m. – 3:05 p.m. Treatment of bladder fibrosis through tissue engineering and the use of bio materials in regenerative bladder augmentation
Bradley Kropp, MD, University of Oklahoma

3:05 p.m. – 3:30 p.m. Use of nanotechnology to treat high grade non-muscle invasive bladder cancer
Shad Thaxton, MD, PhD, Northwestern University

SESSION B: Modeling and treating renal disease

Location:

1:30 p.m. – 1:35 p.m. Welcome and Overview
Wendy Huss, PhD, Roswell Park Cancer Institute, Chair

1:35 p.m. – 2:05 p.m. Chronic kidney disease (CKD) and acute kidney injury (AKI): New perspectives and research opportunities
Steven Campbell, MD, PhD, Cleveland Clinic

2:05 p.m. – 2:35 p.m. Putative imaging predictive biomarkers for mTOR and VEGF pathway directed agents.
Walter Stadler, MD., University of Chicago

2:35 p.m. – 3:05 p.m. Using Mouse Models to Study Renal Oncogenesis.
Peter Clark, MD, Vanderbilt University Medical Center

3:05 p.m. – 3:30 p.m. Upstream regulation of HIF-alpha by Nox4 oxidative signaling.
Jodi Maranchie, MD, University of Pittsburgh